Boston Scientific Co. (NYSE:BSX) Stock Position Increased by Stifel Financial Corp

Stifel Financial Corp lifted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,008,281 shares of the medical equipment provider's stock after acquiring an additional 12,040 shares during the period. Stifel Financial Corp owned 0.14% of Boston Scientific worth $168,294,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. SageView Advisory Group LLC lifted its position in Boston Scientific by 2.9% during the third quarter. SageView Advisory Group LLC now owns 9,261 shares of the medical equipment provider's stock worth $776,000 after buying an additional 259 shares during the period. Quadrature Capital Ltd purchased a new position in Boston Scientific during the third quarter worth about $4,798,000. Quantinno Capital Management LP lifted its position in Boston Scientific by 36.0% during the third quarter. Quantinno Capital Management LP now owns 91,089 shares of the medical equipment provider's stock worth $7,633,000 after buying an additional 24,088 shares during the period. Quarry LP lifted its position in Boston Scientific by 81.4% during the third quarter. Quarry LP now owns 780 shares of the medical equipment provider's stock worth $65,000 after buying an additional 350 shares during the period. Finally, Royal London Asset Management Ltd. lifted its position in Boston Scientific by 3.7% during the third quarter. Royal London Asset Management Ltd. now owns 635,079 shares of the medical equipment provider's stock worth $53,220,000 after buying an additional 22,525 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.5 %

NYSE BSX traded down $0.46 during mid-day trading on Friday, reaching $90.07. 3,021,319 shares of the company's stock traded hands, compared to its average volume of 6,012,767. Boston Scientific Co. has a 1-year low of $54.52 and a 1-year high of $91.93. The company has a fifty day simple moving average of $87.27 and a 200-day simple moving average of $81.16. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a market cap of $132.75 billion, a price-to-earnings ratio of 74.44, a P/E/G ratio of 2.66 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business's revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 EPS. As a group, equities research analysts expect that Boston Scientific Co. will post 2.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BSX. Royal Bank of Canada increased their target price on Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Monday, November 4th. Stifel Nicolaus raised their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Citigroup raised their price objective on Boston Scientific from $92.00 to $98.00 and gave the stock a "buy" rating in a report on Thursday, October 24th. Finally, BTIG Research raised their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $93.39.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company's stock, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 328,157 shares of company stock valued at $27,957,676. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.